Richard Gonzalez, AP Images

House com­mit­tee un­cov­ers how Hu­mi­ra’s price spiked by 470% as Ab­b­Vie ex­ecs cashed bonus­es tied to the hikes

Pri­or to the House Com­mit­tee on Over­sight’s grilling of Ab­b­Vie CEO Richard Gon­za­lez on Tues­day, the com­mit­tee staff re­leased a 57-page re­port fol­low­ing a two year in­ves­ti­ga­tion in­to how and why the com­pa­ny spiked the price of Hu­mi­ra (adal­i­mum­ab) and made it the high­est-gross­ing drug of all time.

While the com­mit­tee in­ves­ti­ga­tion and pub­lic lash­ing aren’t like­ly to do ac­tu­al dam­age to Ab­b­Vie’s bot­tom line or bring new Hu­mi­ra biosim­i­lar com­pe­ti­tion be­fore 2023 in the US, the re­port digs in­to how Ab­b­Vie used more than two dozen price in­creas­es, shad­ow pric­ing with Am­gen’s block­buster En­brel, and patent thick­ets to block com­pe­ti­tion while amass­ing more than $170 bil­lion in net rev­enue from Hu­mi­ra since 2003.

Reps. Car­olyn Mal­oney (D-NY), chair of the Over­sight Com­mit­tee, Jar­rold Nadler (D-NY), chair of the House Ju­di­cia­ry Com­mit­tee, and sub­com­mit­tee chair David Ci­cilline (D-RI) al­so sent a let­ter to the Fed­er­al Trade Com­mis­sion on Tues­day, call­ing for a for­mal in­quiry in­to Ab­b­Vie’s ac­tions to de­lay the en­try of Hu­mi­ra biosim­i­lars in the US (more on the de­lays be­low).

Price In­creas­es

Near­ly a decade af­ter Ab­bott Lab­o­ra­to­ries first launched Hu­mi­ra in 2003, the list price rose from $522 per 40-mil­ligram sy­ringe to $1,024 by 2013, with 13 price hikes, pri­or to spin­ning off Ab­b­Vie as a sep­a­rate com­pa­ny. Un­der Ab­b­Vie, the price of Hu­mi­ra spiked an­oth­er 14 times, in­clud­ing by 30% with­in a 10-month win­dow.

“Hu­mi­ra is now priced at $2,984 per sy­ringe, or $77,586 an­nu­al­ly — a 470% in­crease from when the drug en­tered mar­ket,” the re­port says.

And those con­sis­tent price hikes were dri­ven by ex­ec­u­tive bonus­es from 2015 to 2018, which were di­rect­ly linked to Hu­mi­ra’s fi­nan­cial per­for­mance, the re­port says.

In that first year that the in­cen­tives were cre­at­ed, ex­ecs pushed Hu­mi­ra’s US net rev­enue to rise from $6.5 bil­lion in 2014 to $8.4 bil­lion in 2015, af­ter Ab­b­Vie ex­ec­u­tives im­ple­ment­ed a 9.9% price in­crease in April 2015 — the largest-ever price in­crease for the drug — and a 7.9% price in­crease in Au­gust 2015.

While Gon­za­lez will like­ly tell Con­gress Tues­day that the price in­creas­es were used to fund more re­search & de­vel­op­ment, the com­mit­tee shows that wasn’t the case.

“Ab­b­Vie’s to­tal re­search and de­vel­op­ment ex­pen­di­tures for Hu­mi­ra rep­re­sent­ed on­ly a small frac­tion of its net rev­enue from this drug. In re­sponse to the Com­mit­tee’s re­quest, Ab­b­Vie iden­ti­fied a to­tal of $5.19 bil­lion in ‘Hu­mi­ra Re­search & De­vel­op­ment’ be­tween 2009 and 2018 — ap­prox­i­mate­ly 7.4% of its Hu­mi­ra U.S. net rev­enue and 4.2% of its Hu­mi­ra world­wide net rev­enue over that pe­ri­od,” the re­port shows.

What the US would’ve saved

The re­port al­so tracks how much the US gov­ern­ment could’ve saved over­all by fac­tor­ing in some of the dis­counts that some fed­er­al de­part­ments re­ceive. Over­all, Ab­b­Vie’s Hu­mi­ra net rev­enue from Medicare — a fig­ure that sub­tracts dis­counts and re­bates— was $9.9 bil­lion from 2010 to 2018.

“If Medicare had re­ceived the same dis­counts as the De­part­ment of De­fense, it would have saved more than $7.4 bil­lion on Hu­mi­ra from 2010 to 2018. Sim­i­lar­ly, if Medicare had re­ceived the same dis­counts as the De­part­ment of Vet­er­ans Af­fairs, it would have saved $7 bil­lion on Hu­mi­ra from 2010 to 2018,” the re­port notes.

Re­pub­li­cans in Con­gress have fo­cused their at­ten­tion less on low­er­ing drug prices and more on low­er­ing out-of-pock­et costs, the re­port re­veals how out-of-pock­et costs for Hu­mi­ra have spiked too.

A 2019 Kaiser Fam­i­ly Foun­da­tion study found that the me­di­an an­nu­al out-of-pock­et cost for Medicare pa­tients on Hu­mi­ra was $5,471 in 2019, which is $606 more than in 2016.

A re­tired teacher and Medicare ben­e­fi­cia­ry with Crohn’s dis­ease told the com­mit­tee that de­spite hav­ing a sup­ple­men­tal health in­sur­ance plan, her out-of-pock­et costs for Hu­mi­ra were more than $2,600 for a month’s sup­ply, pre­vent­ing her from re­ceiv­ing treat­ment.

Rock­ford, Illi­nois May­or Tom Mc­Na­ma­ra al­so re­port­ed that be­tween Au­gust 2013 and Ju­ly 2020, his city spent more than $2.5 mil­lion on Hu­mi­ra alone, which means more than 5% of the city’s em­ploy­ee health plan ex­pen­di­tures were for Hu­mi­ra.

Don’t blame the play­er, blame the game?

In ad­di­tion to rais­ing the price, Ab­b­Vie al­so halt­ed any po­ten­tial com­pe­ti­tion un­til 2023 (de­spite the launch of Hu­mi­ra biosim­i­lars in Eu­rope in 2018), and that sup­pres­sion oc­curred even be­yond Ab­b­Vie’s own in­ter­nal pro­jec­tions.

In Feb­ru­ary 2014, ac­cord­ing to the com­mit­tee re­port, Ab­b­Vie ex­ec­u­tives cir­cu­lat­ed a pre­sen­ta­tion on “US Hu­mi­ra Biosim­i­lar Ero­sion” that pro­ject­ed that three to five biosim­i­lar com­peti­tors would en­ter the mar­ket by the first quar­ter of 2017.

What’s more, Ab­b­Vie’s patent on Hu­mi­ra’s ac­tive in­gre­di­ent ex­pired on De­cem­ber 31, 2016.

“At that time, com­peti­tors should have been free to en­ter the mar­ket. How­ev­er, the com­pa­ny ex­ploit­ed the patent sys­tem to ob­tain or ap­ply for over 200 ad­di­tion­al patents on Hu­mi­ra to block biosim­i­lar com­pe­ti­tion,” the re­port says.

Am­gen’s block­buster bi­o­log­ic En­brel, which won’t see biosim­i­lar com­pe­ti­tion in the US un­til 2029, is al­so one of Hu­mi­ra’s top com­peti­tors, and the com­mit­tee showed how the two com­pa­nies raised the prices of their drugs in lock-step with each oth­er.

“In­ter­nal Ab­b­Vie doc­u­ments ob­tained by the Com­mit­tee re­veal that the com­pa­ny viewed Am­gen’s price in­creas­es as pro­vid­ing cov­er for its own price in­creas­es. For ex­am­ple, one com­pa­ny ex­ec­u­tive re­port­ed to the cur­rent CEO and then-Ex­ec­u­tive Vice Pres­i­dent Richard Gon­za­lez that it was a ‘Great week-end’ af­ter learn­ing that Am­gen had in­creased the price of En­brel on Jan­u­ary 20, 2012, to $25,150 an­nu­al­ly. The email thread not­ed that ear­li­er that month, Ab­b­Vie had in­creased the price of Hu­mi­ra to $24,913 an­nu­al­ly. In Ju­ly, Ab­b­Vie would top Am­gen again by rais­ing the price of Hu­mi­ra to $26,632. Less than 3 weeks lat­er, Am­gen fol­lowed suit with an­oth­er price in­crease,” the re­port says.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.